Mezzion Reports Pre-IND FDA Feedback on the Development of Udenafil in ADPKD

SEOUL, South Korea, May 7, 2026 /PRNewswire/ -- Mezzion Pharma Co., Ltd. today announced written feedback from the U.S. Food and Drug Administration (FDA) following a pre-IND Type C Guidance meeting interaction for the development of udenafil in autosomal dominant polycystic kidney...